background
chronic
obstruct
pulmonari
diseas
copd
heterogen
diseas
character
frequent
exacerb
phenotyp
independ
diseas
stage
increas
evid
show
microbiota
play
role
diseas
progress
sever
longterm
intern
multicent
assess
variat
viral
bacteri
commun
driver
exacerb
lack
method
twohundr
sever
copd
patient
europ
north
america
follow
longitudin
year
perform
nucleic
acid
detect
respiratori
virus
ribosom
rna
gene
sequenc
evalu
bacteri
microbiota
sputum
sampl
collect
stabl
acut
exacerb
followup
visit
result
similar
viral
bacteri
taxa
found
patient
usa
compar
bulgaria
czech
republ
microbiom
divers
significantli
differ
p
impact
exacerb
rate
viru
infect
strongli
associ
exacerb
event
p
human
rhinoviru
coronaviru
influenza
viru
constitut
top
viral
pathogen
trigger
exacerb
moraxella
haemophilu
like
domin
microbiota
exacerb
event
presenc
proteobacteria
pseudomona
staphylococcu
amongst
other
associ
exacerb
event
p
strongli
associ
exacerb
frequenc
p
confirm
longitudin
variat
biotyp
bacteri
microbiota
suggest
role
microbiota
sensit
lung
conclus
studi
highlight
bacteri
taxa
lung
sensit
viral
trigger
copd
exacerb
provid
global
overview
divers
target
drug
develop
explor
new
microbiom
analysi
method
guid
futur
patient
manag
applic
chronic
obstruct
pulmonari
diseas
copd
defin
airflow
limit
encompass
sever
lung
diseas
heterogen
includ
differ
clinic
characterist
sourc
inflamm
respons
therapi
caus
exacerb
copd
progress
exacerb
becom
frequent
sever
exacerb
rate
reflect
independ
suscept
phenotyp
could
mediat
host
factor
environment
factor
viral
infect
andor
bacteri
microbiom
infect
predomin
caus
copd
exacerb
approxim
half
report
caus
bacteri
infect
includ
non
typeabl
haemophilu
influenza
nthi
moraxella
catarrhali
streptococcu
pneumonia
pseudomona
aeruginosa
half
viral
infect
primarili
human
rhinoviru
hrv
also
influenza
viru
coronaviru
respiratori
syncyti
viru
rsv
name
bacteria
virus
also
frequent
isol
airway
stabl
copd
patient
advent
cultureindepend
test
suggest
viral
persist
colon
lower
airway
resid
bacteri
microbiota
implic
role
microbiota
diseas
pathogenesi
progress
treatment
outcom
lung
diseas
studi
microbiom
provid
new
framework
understand
hostpathogen
interact
also
yield
new
marker
patient
diagnosi
manag
microbiota
divers
seen
potenti
biomark
case
singl
pathogen
organ
reduc
commun
complex
bacteri
vaginosi
crohn
diseas
lung
microbi
dysbiosi
copd
character
decreas
divers
may
contribut
alter
immun
respons
environment
insult
dysbiosi
time
copd
exacerb
contribut
increas
diseas
sever
higher
mortal
rate
geographi
could
also
potenti
covari
copd
patient
microbiota
gut
microbiota
shown
geograph
variabl
previou
studi
differ
conntri
evalu
copd
microbiota
effect
geograph
variat
yet
evalu
singl
studi
relat
diseas
sever
present
cohort
stem
studi
incid
viral
infect
copd
patient
enrol
europ
north
america
follow
rsv
season
schedul
well
visit
unschedul
ill
visit
understand
copd
exacerb
dynam
retrospect
evalu
sputum
bacteri
microbiota
subset
studi
goal
identifi
differ
patient
higher
rate
exacerb
assess
geograph
differ
microbiota
europ
usa
determin
influenc
viral
infect
microbiota
divers
frequenc
exacerb
patient
cohort
part
observ
studi
incid
acut
respiratori
ill
ari
event
lead
worsen
cardiorespiratori
statu
copd
clinicaltrialsgov
protocol
approv
independ
institut
review
board
subject
sign
written
inform
consent
enrol
studi
popul
includ
adult
year
age
copd
recruit
site
bulgaria
site
czech
republ
site
across
usa
fall
spring
fig
cohort
bulgaria
czech
republ
show
similar
characterist
analyz
jointli
europ
fig
sampl
timelin
composit
timelin
oct
may
copd
patient
enrol
sampl
schedul
well
visit
blue
arrow
unschedul
visit
red
purpl
arrow
within
day
acut
exacerb
exacerb
followup
visit
sampl
consid
stabl
collect
day
posthospit
ari
dot
arrow
correspond
sampl
collect
schedul
well
visit
incident
correspond
acut
exacerb
event
exacerb
followup
visit
piechart
repres
proport
patient
europ
usa
b
proport
sampl
collect
diseas
state
c
proport
sampl
associ
antibiot
abx
inhal
corticosteroid
cs
taken
past
day
eas
represent
subject
schedul
well
visit
may
octob
year
obtain
sputum
clinic
data
fig
unschedul
ill
visit
collect
sputum
clinic
data
perform
subject
experienc
ari
acut
exacerb
copd
symptom
followup
ill
visit
sampl
consid
stabl
collect
least
day
last
day
hospit
last
ari
acut
exacerb
event
requir
hospit
acut
exacerb
sampl
collect
within
h
event
addit
sampl
collect
day
acut
exacerb
event
unschedul
visit
fig
c
patient
character
frequent
exacerb
phenotyp
experienc
exacerb
event
per
year
investig
drug
administ
studi
subject
physician
prescrib
record
treatment
deem
necessari
provid
adequ
support
care
sampl
collect
day
follow
treatment
consid
treatment
associ
fig
spontan
rather
induc
sputum
collect
possibl
sever
copd
studi
subset
follow
standard
collect
visit
subject
ask
gargl
water
immedi
prior
sputum
collect
reduc
number
oral
bacteria
subject
ask
cough
deepli
expector
cup
mix
cold
transport
media
kept
genmark
respiratori
viru
panel
genmark
diagnost
inc
carlsbad
ca
use
detect
common
respiratori
virus
sputum
sampl
rsv
detect
confirm
rtpcr
previous
describ
addit
rtpcr
use
primer
hrv
use
detect
human
rhinoviru
subtyp
bacteri
genom
dna
extract
singl
central
lab
use
zymobiom
dna
kit
zymo
california
usa
follow
manufactur
instruct
hypervari
region
rrna
gene
pcr
amplifi
sequenc
use
illumina
miseq
platform
along
neg
control
zymobiom
microbi
commun
dna
standard
phix
librari
qualiti
control
rrna
gene
sequenc
analys
use
version
softwar
packag
wrap
use
correct
sequenc
obtain
annot
sequenc
variant
asv
taxonomi
assign
use
bay
classifi
train
greengen
databas
version
cluster
ident
sequenc
align
perform
mafft
mask
use
fasttre
build
phylogenet
tree
alphadivers
metric
beta
divers
metric
princip
coordin
analysi
pcoa
estim
sampl
rarefi
sequenc
per
sampl
signific
featur
interest
retest
use
nonrarefi
alpha
beta
divers
estim
analysi
composit
ancom
use
differenti
taxa
abund
calcul
nonrarefi
data
ancom
account
structur
data
control
fals
discoveri
rate
microbiota
profil
cluster
biotyp
use
biotyp
packag
r
longitudin
microbiota
variat
stabl
time
point
assess
calcul
median
weight
unifrac
distanc
patient
least
stabl
sampl
patient
categor
bottom
top
quartil
withinpati
stabl
sampl
median
unifrac
distanc
respect
associ
microbiota
viral
compon
demograph
clinic
data
calcul
r
use
fisher
test
categor
variabl
welsh
ttest
comparison
mean
continu
variabl
chisquar
test
compar
expect
frequenc
odd
ratio
calcul
use
questionr
packag
r
associ
microbi
divers
demograph
clinic
data
calcul
divers
plugin
use
group
pairwis
kruskalw
test
correct
fals
discoveri
rate
analysi
alpha
divers
permanova
follow
permut
analysi
beta
divers
distanc
cohort
compos
patient
europ
bulgaria
czech
republ
usa
fig
tabl
patient
present
sever
sever
copd
patient
europ
usa
match
age
sex
gold
stage
enrol
forc
expiratori
volum
percent
predict
comorbid
congest
heart
failur
diabet
hypertens
malign
similar
europ
usa
usa
patient
significantli
higher
smoke
histori
packyear
longer
copd
durat
number
exacerb
per
year
number
frequent
exacerb
phenotyp
defin
exacerbationsyear
higher
usa
compar
europ
statist
signific
tabl
total
sputum
sampl
collect
patient
year
similar
proport
sampl
collect
acut
exacerb
europ
usa
supplementari
tabl
approxim
sampl
associ
antibiot
corticosteroid
treatment
respect
significantli
sampl
collect
usa
associ
antibiot
treatment
supplementari
tabl
analysi
bacteri
taxa
sputum
sampl
show
phyla
commonli
observ
lung
microbiota
firmicut
proteobacteria
bacteroidet
repres
major
phyla
identifi
fig
prevotella
veillonella
streptococcu
haemophilu
repres
preval
bacteri
genera
fig
sampl
european
patient
bacteroidet
less
proteobacteria
overal
sampl
usa
patient
within
phylum
firmicut
usa
patient
streptococcu
veillonella
compar
european
patient
fig
microbiota
predomin
prevotella
streptococcu
veillonella
found
major
sampl
fig
prevotella
streptococcu
veillonella
repres
major
microbiota
sampl
collect
stabl
state
haemophilu
moraxella
predomin
acut
exacerb
sampl
pseudomona
preval
exacerb
followup
sampl
fig
viral
test
sputum
sampl
show
sputum
sampl
posit
least
one
viru
hrv
found
largest
proport
sampl
follow
coronaviru
influenza
viru
fig
virus
except
adenovirus
detect
frequent
acut
exacerb
followup
visit
stabl
fig
signific
differ
viral
incid
europ
usa
except
coronaviru
influenza
b
viru
rsv
supplementari
tabl
alpha
divers
metric
number
observ
asv
shannon
even
faith
phylogenet
divers
pd
index
repres
mean
number
taxon
respect
shannon
divers
index
p
p
p
lower
higher
statist
signific
divers
compar
averag
note
red
blue
respect
hmpv
human
metapneumoviru
sampl
sometim
weight
phylogenet
related
overal
sampl
usa
patient
significantli
lower
shannon
divers
index
europ
fig
even
correct
antibiot
use
clinic
site
supplementari
fig
year
sever
copd
smoke
packyear
associ
differ
microbiota
divers
significantli
geographi
supplementari
tabl
signific
differ
number
observ
asv
faith
pd
index
observ
exacerb
compar
stabl
sampl
supplementari
tabl
prevotellapredomin
microbiota
show
highest
alpha
divers
sampl
predomin
escherichia
haemophilu
pseudomona
lowest
alpha
divers
fig
signific
differ
microbi
divers
sampl
infect
viru
sampl
infect
differ
virus
fig
beta
divers
metric
weight
unifrac
robust
aitchison
pca
use
compar
microbiota
commun
result
distanc
matric
princip
coordin
visual
weight
unifrac
distanc
support
conclus
show
differ
geographi
predomin
bacteria
affect
type
viral
infect
supplementari
fig
result
also
support
test
nonrarefi
alpha
betadivers
estim
geographi
p
domin
bacteri
genu
p
virus
p
associ
signific
chang
divers
data
shown
odd
ratio
acut
exacerb
event
frequent
exacerb
event
year
calcul
demograph
clinic
data
viral
infect
abund
certain
bacteri
taxa
lung
microbiota
fig
viral
infect
strongli
associ
exacerb
event
frequent
exacerb
parainfluenzavirus
piv
influenza
b
viru
rsv
b
highest
odd
ratio
exacerb
event
fig
interestingli
influenza
b
viru
neg
correl
frequent
exacerb
detect
patient
exacerb
infrequ
bacteria
strongli
associ
exacerb
frequenc
exacerb
event
presenc
higher
abund
enterococcu
lactobacillu
moraxella
pseudomona
staphylococcu
streptococcu
correl
frequent
exacerb
neisseria
prevotella
veillonella
significantli
associ
lower
exacerb
frequenc
fig
interestingli
top
quartil
abund
odd
ratio
genu
haemophilu
associ
higher
exacerb
rate
effect
howev
seem
mediat
hparainfluenza
note
differenti
abund
bacteri
taxa
significantli
associ
exacerb
event
taxa
associ
exacerb
frequenc
supplementari
fig
high
ecoli
lactobacillu
staphylococcu
stabl
sampl
potenti
predictor
frequent
exacerb
supplementari
fig
patient
hypertens
significantli
higher
odd
ratio
frequent
copd
exacerb
fig
comorbid
significantli
influenc
exacerb
frequenc
quantifi
tempor
variabl
sputum
microbiota
stabl
state
within
individu
subject
patient
longitudin
stabl
sampl
calcul
median
weight
unifrac
distanc
categor
top
bottom
quartil
patient
consist
variabl
microbiota
time
fig
patient
variabl
sputum
microbiota
median
weight
unifrac
like
higher
rel
abund
bacillu
escherichia
lactobacillu
moraxella
staphylococcu
fig
supplementari
fig
microbiota
variabl
seemingli
stabl
diseas
state
associ
higher
exacerb
frequenc
frequent
viral
infect
fig
longitudin
sampl
also
enabl
assess
recurr
viral
infect
viral
speci
strain
subtyp
consecut
sampl
virus
detect
consecut
sampl
patient
fig
time
beween
consecut
sampl
rang
day
year
virus
detect
within
week
sampl
correspond
probabl
typic
singl
infect
includ
detect
coronaviru
hrv
rsv
b
virus
detect
patient
day
apart
may
correspond
chronic
recurr
infect
adenoviru
c
coronaviru
hrv
hrv
b
hrv
c
detect
eighteen
sampl
patient
correspond
acut
exacerb
event
patient
frequent
exacerb
fig
sought
defin
common
microbiota
cluster
associ
clinic
characterist
microbiota
stabl
sampl
could
separ
biotyp
indic
highest
calinskiharabasz
ch
index
follow
iter
partitioningaroundmedoid
cluster
analysi
jensenshannon
distanc
betweenclass
analysi
show
major
cluster
biotyp
repres
neisseria
veillonella
biotyp
repres
streptococcu
rothia
fig
sampl
high
rel
abund
streptococcusrothia
biotyp
found
greater
proport
usa
patient
associ
longer
histori
copd
less
frequent
detect
virus
stabl
visit
fig
sampl
acut
exacerb
visit
could
separ
biotyp
character
high
rel
abund
either
prevotella
biotyp
streptococcu
biotyp
haemophilu
biotyp
fig
risk
factor
copd
exacerb
adjust
odd
ratio
viral
infect
b
bacteri
abund
topbottom
quartil
c
demograph
clinic
histori
featur
associ
acut
exacerb
event
patient
frequent
exacerb
event
year
signific
present
red
posit
associ
green
neg
associ
orang
dot
repres
nonsignific
odd
ratio
horizont
bar
repres
confid
interv
genera
name
bold
speci
italic
fig
streptococcu
haemophilu
found
major
usa
sampl
associ
longer
copd
durat
higher
exacerb
frequenc
antibiot
corticosteroid
use
significantli
correl
higher
viral
infect
fig
exacerb
followup
sampl
divers
could
optim
cluster
biotyp
biotyp
character
high
rel
abund
pseudomona
significantli
associ
longer
copd
durat
antibiot
use
biotyp
character
high
rel
abund
streptococcu
rothia
significantli
associ
higher
exacerb
frequenc
biotyp
significantli
associ
clinic
characterist
fig
biotyp
show
microbiota
profil
divers
dynam
depend
diseas
state
understand
presenc
role
bacteri
viral
pathogen
time
heterogen
dynam
copd
diseas
need
patient
treatment
manag
character
rrna
gene
microbiota
respiratori
virus
longitudin
intern
cohort
sever
copd
patient
describ
studi
provid
largest
survey
date
complex
associ
copd
patient
particularli
suscept
respiratori
infect
hrv
identifi
promin
agent
respiratori
tract
infect
cohort
copd
patient
viral
character
particular
import
report
exist
divers
respiratori
viral
agent
copd
viral
divers
account
design
new
treatment
particular
newli
describ
hrv
c
detect
sampl
patient
present
cohort
report
previous
detect
virus
stabl
sampl
asymptomat
viral
infect
copd
patient
common
howev
role
asymptomat
infect
diseas
progress
unclear
respiratori
virus
test
show
highli
signific
posit
odd
ratio
exacerb
event
lower
signific
regard
exacerb
frequenc
may
indic
viral
infect
alon
sensit
lung
repeat
exacerb
much
bacteri
microbiota
interestingli
similar
trend
shown
asthma
respiratori
viral
infect
earli
life
result
microbiom
chang
hypersensit
predisposit
lead
asthma
repeat
viral
detect
frequent
patient
frequent
exacerb
phenotyp
number
small
contradict
report
exist
repeat
detect
singl
viru
copd
complet
viral
genom
character
need
understand
natur
viral
infect
advent
cultureindepend
techniqu
appear
microbiom
harbor
potenti
bacteri
pathogen
character
elsewher
portion
develop
exacerbationpron
phenotyp
phenotyp
appear
independ
diseas
gold
stage
yet
link
microbiota
divers
previous
observ
microbiota
divers
copd
lung
correl
diseas
sever
diseas
state
microbiota
divers
alon
correl
frequent
exacerb
highli
correl
certain
bacteri
taxa
domin
microbiota
microbiota
predomin
escherichia
pseudomona
streptococcu
show
significantli
lower
alpha
divers
signific
posit
odd
ratio
frequent
exacerb
phenotyp
suggest
role
microbiota
sensit
copd
lung
acut
exacerb
studi
limit
diseas
sever
metric
except
baselin
evalu
sampl
event
longitudin
monitor
symptom
scale
would
help
better
understand
relat
certain
bacteria
exacerb
frequenc
also
symptom
sever
copd
progress
use
biotyp
seldom
use
respiratori
microbiota
research
yet
explor
copd
complex
resid
bacteri
commun
could
identifi
copd
sputum
sampl
categor
biotyp
stabl
acut
exacerb
exacerb
followup
visit
respect
biotyp
stabl
state
associ
higher
viral
infect
biotyp
acut
exacerb
associ
high
exacerb
frequenc
find
interest
mirror
anoth
studi
show
partit
copd
exacerb
sampl
cytokin
profil
cluster
associ
specif
ratio
proteobacteria
firmicut
bacteroidet
highlight
heterogen
exacerb
profil
copd
patient
exacerb
followup
visit
biotyp
high
rel
abund
pseudomona
found
overrepres
sampl
associ
antibiot
use
antibiot
treatment
inadequaci
caus
secondari
infect
emerg
multidrug
resist
paeruginosa
new
target
treatment
monoclon
antibodi
could
use
set
princip
novelti
studi
cohort
long
term
patient
followup
abl
collect
sever
sputum
sampl
per
patient
stabl
state
cours
year
studi
copd
microbiota
longitudin
lung
microbiom
inher
variabl
shape
process
inhal
elimin
lung
microbiom
also
person
larg
interpati
variabl
previous
shown
microbi
dysbiosi
stabl
exacerb
state
correl
greater
exacerb
sever
patient
greater
microbiota
variabl
stabl
state
correl
higher
exacerb
frequenc
proteobacteria
pseudomona
moraxella
abund
patient
variabl
microbiota
stabl
state
interestingli
paeruginosa
mcattharali
promin
caus
exacerb
role
stabl
diseas
less
clear
previous
shown
chronic
colon
p
aeruginosa
occur
frequent
sever
copd
patient
mcatarrhali
asymptomat
colon
associ
greater
frequenc
sputum
iga
respons
exacerb
result
suggest
dysbiot
burden
stabl
state
pseudomona
moraxella
other
might
sensit
lung
exacerb
viral
infect
pseudomona
moraxella
like
mani
opportunist
proteobacteria
proinflammatori
imbalanc
inflamm
improv
paeruginosa
fit
allow
acquisit
new
mcattharali
strain
lead
exacerb
possibl
infect
pathogen
coupl
cycl
inflamm
dysbiosi
microbiolog
clinic
test
copd
patient
often
perform
exacerb
followup
visit
patient
might
benefit
clinic
monitor
bacteria
stabl
state
assess
presenc
andor
growth
could
lead
potenti
futur
exacerb
also
note
geograph
differ
copd
lung
microbiota
geograph
differ
gut
microbiota
previous
note
yet
lung
signific
differ
alpha
beta
divers
usa
europ
within
countri
site
microbiota
divers
usa
lower
although
frequent
exacerb
phenotyp
common
europ
differ
signific
usa
patient
tend
sampl
high
rel
abund
streptococcu
biotyp
haemophilu
biotyp
associ
frequent
exacerb
phenotyp
spneumonia
hinfluenza
commonli
associ
exacerb
also
consid
potenti
risk
factor
frequent
exacerb
phenotyp
significantli
sampl
collect
usa
associ
antibiot
use
alon
explain
differ
divers
observ
studi
includ
varieti
standardofcar
medic
dose
time
preclud
precis
treatment
effect
model
microbiota
clinic
trial
explor
current
novel
treatment
modal
lead
better
patient
manag
antibiot
stewardship
review
elsewher
predomin
haemophilu
overrepres
acut
exacerb
sampl
fig
note
previou
studi
howev
interestingli
use
odd
ratio
fig
ancom
suppplementari
fig
haemophilu
abund
hinfluenza
high
significantli
associ
acut
exacerb
event
wherea
hparainfluenza
significantli
higher
stabl
state
differ
haemophilu
abund
compar
studi
might
due
type
sputum
collect
transport
media
extract
protocol
effect
sampl
size
although
hparainfluenza
caus
respiratori
infect
healthi
subject
associ
exacerb
copd
hparainfluenza
could
compet
nich
resourc
lead
overgrowth
pathogen
hinfluenza
previou
work
shown
hinfluenza
compet
spneumonia
patient
colon
nthi
acquir
hrv
frequent
sever
exacerb
streptococcu
speci
could
resolv
use
rrna
region
although
speciat
haemophilu
attempt
valid
use
target
pcr
whole
genom
sequenc
necessari
ensur
correct
discrimin
note
constant
improv
databas
also
affect
taxonom
resolut
silva
databas
version
updat
classifi
read
genera
n
compar
greengen
version
updat
n
howev
bacteri
taxa
discuss
studi
show
less
variat
read
classif
databas
classifi
data
shown
conclus
unchang
speciat
type
bacteria
virus
critic
understand
pathogen
complex
relationship
greater
taxonom
resolut
achiev
use
updat
databas
comprehens
techniqu
like
shotgun
metagenom
summari
studi
provid
broad
survey
virus
bacteria
colon
sever
copd
patient
provid
clinician
potenti
target
clinic
test
patient
treatment
demonstr
viral
infect
strongli
associ
acut
exacerb
event
particular
compon
microbiota
associ
higher
exacerb
frequenc
geograph
longitudin
differ
lung
copd
microbiota
exist
correl
exacerb
outcom
stabl
state
longitudin
microbiota
monitor
biotyp
could
lead
identif
potenti
biomark
indic
futur
exacerb
bacteri
sensit
comprehens
microbiota
profil
respiratori
viral
detect
use
develop
antimicrobi
agent
therapeut
intervent
better
patient
manag
supplementari
inform
accompani
paper
http
addit
file
tabl
sampl
characterist
tabl
statist
signific
alpha
beta
microbiota
divers
metric
demograph
clinic
variabl
use
divers
plugin
figur
shannon
divers
follow
antibiot
treatment
europ
usa
patient
figur
microbiota
composit
divers
across
studi
site
figur
princip
coordin
analysi
weight
unifrac
distanc
sputum
microbiota
color
geographi
sampl
type
b
predomin
bacteri
taxa
c
viral
infect
figur
bacteria
associ
copd
exacerb
frequenc
exacerb
abund
moraxella
hparainfluenza
identifi
analysi
composit
ancom
microbiota
stabl
exacerb
sampl
b
cladogram
bacteri
taxa
identifi
ancom
compar
frequent
exacerb
event
year
infrequ
exacerb
figur
adjust
odd
ratio
bacteri
abund
topbottom
quartil
stabl
sampl
associ
frequent
exacerb
figur
cladogram
differenti
abund
bacteri
taxa
identifi
ancom
compar
consist
variabl
longitudin
microbiota
patient
profil
stabl
state
